ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Psoriatic arthritis"

  • Abstract Number: L03 • ACR Convergence 2020

    Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial

    Philip Mease1, Atul Deodhar2, Désirée van der Heijde3, Frank Behrens4, Alan Kivitz5, Jonghyeon Kim6, Shalabh Singhal6, Miroslawa Nowak6 and Subhashis Banerjee6, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 2Oregon Health & Science University, Portland, OR, 3Leiden University Medical Center, Leiden, Netherlands, 4CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, 5Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, 6Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates signaling by key cytokines involved in psoriatic arthritis (PsA) pathophysiology. Deucravacitinib (BMS-986165) is a…
  • Abstract Number: 0169 • ACR Convergence 2020

    Patient-Reported Outcomes Differentiate Between Remission and Low Disease Activity in Psoriatic Arthritis

    Juliette Yedimenko1, Jessica Walsh2, Alexis Ogdie3, Yuxuan Jin1, Soumya Reddy4, Jose Scher5 and M. Elaine Husni1, 1Cleveland Clinic, Cleveland, OH, 2University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, 3Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 4NYU School of Medicine, New York, NY, 5NYU School of Medicine, New York City

    Background/Purpose: For psoriatic arthritis (PsA), several different composite instruments are available to define low disease activity (LDA) and remission (REM) targets for treatment. Patient-reported outcomes…
  • Abstract Number: 0318 • ACR Convergence 2020

    Oxylipin Profile Is Associated with Skin Disease and Enthesitis in Psoriatic Disease

    Roxana Coras1, Arthur Kavanaugh2, Angela Kluzniak3, Dustina Holt3, Amy Weilgosz3, Oswald Quehenberger1, Christopher Ritchlin4 and Monica Guma5, 1University of California San Diego, La Jolla, CA, 2Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, 3University of Rochester Medical Center, New York, NY, 4Department of Medicine, University of Rochester Medical Center, Rochester, NY, 5Division of Rheumatology, University of California San Diego, Department of Medicine, Autonomous University of Barcelona, La Jolla, CA

    Background/Purpose: Psoriatic arthritis (PsA), a systemic inflammatory disease, occurs in about 25% of patients with psoriasis (PsO). At present, there are no biomarkers that reliably…
  • Abstract Number: 0334 • ACR Convergence 2020

    Comparative Efficacy of Guselkumab in Patients with Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis

    Philip Mease1, Iain McInnes2, Kiefer Eaton3, Steven Peterson4, Tim Disher5, Soumya Chakravarty6, Chetan Karyekar7, Sandhya Nair8, Wolf-Henning Boehncke9 and Christopher Ritchlin10, 1Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 2Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 3EVERSANA, Burlington, Canada, 4Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, 5EVERSANA, Sydney, Australia, 6Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, 7Janssen Global Services, LLC, Horsham, PA, 8Janssen Pharmaceutica NV, Beerse, 9Geneva University Hospitals, Geneva, Switzerland, 10Department of Medicine, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: The efficacy of the interleukin (IL)-23 subunit p19 inhibitor guselkumab (GUS) for psoriatic arthritis (PsA) has recently been demonstrated in two Phase 3 trials…
  • Abstract Number: 0355 • ACR Convergence 2020

    Collagen Turnover Markers Are Associated with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase-3 Clinical Trial

    Georg Schett1, Matthew J. Loza2, Arumugam Palanichamy2, Oliver FitzGerald3, Christopher Ritchlin4, Frédéric Baribaud5 and Kristen Sweet5, 1Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, 2Janssen Research & Development, LLC, Spring House, 3Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, 4Department of Medicine, University of Rochester Medical Center, Rochester, NY, 5Janssen Research & Development, LLC, Spring House, PA

    Background/Purpose: Guselkumab (GUS), an interleukin-23p19-subunit monoclonal antibody, demonstrated efficacy compared to placebo (PBO) in reducing skin and musculoskeletal signs and symptoms in patients with active…
  • Abstract Number: 0381 • ACR Convergence 2020

    Efficacy of Tofacitinib on Dactylitis in Individual Digits in Patients with Active Psoriatic Arthritis

    Ana-Maria Orbai1, Philip Mease2, Philip Helliwell3, Oliver FitzGerald4, Mohamed Bedaiwi5, Dona Fleishaker6, Rajiv Mundayat6 and Pamela Young7, 1Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, 5Division of Rheumatology, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia, 6Pfizer Inc, Groton, CT, 7Pfizer Inc, Collegeville, PA

    Background/Purpose: Dactylitis, a hallmark of psoriatic arthritis (PsA), is a uniformly diffuse and sometimes painful swelling of the fingers and/or toes.1 Up to 50% of…
  • Abstract Number: 0873 • ACR Convergence 2020

    Impact of Skin Involvement on Disease Burden Among Patients with Psoriatic Arthritis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

    Philip Mease1, Robert McLean2, Taylor Blachley2, Laura Anatale-Tardiff3, Christopher Saffore4, Charlie Lovan5 and Alexis Ogdie6, 1Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 2Corrona, LLC, Waltham, MA, 3Corrona, LLC, Waltham, 4AbbVie Inc., North Chicago, IL, 5AbbVie Inc., North Chicago, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: When deciding to start patients with PsA on biologic therapy, rheumatologists may focus on skin involvement in addition to joint symptoms. The purpose of…
  • Abstract Number: 0907 • ACR Convergence 2020

    Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA)

    Laura Coates1, Dafna Gladman2, Filip Van den Bosch3, Philip Helliwell4, Anna Rychlewska-Hańczewska5, Mykola Stanislavchuk6, Leen Gilles7, Lien Gheyle7, Ke Liu8, Mona Trivedi8, Muhsen Alani9, Robin Besuyen10 and Philip Mease11, 1University of Oxford, Oxford, United Kingdom, 2Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3Ghent University Hospital, Ghent, Belgium, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 5Ai Centrum Medyczne, Poznań, Poland, 6National Pirogov Memorial Medical University, Vinnytsya, Ukraine, 7Galapagos NV, Mechelen, Belgium, 8Gilead Sciences, Inc., Foster City, CA, 9Gilead Sciences, Inc. and University of Washington, Foster City, CA, 10Galapagos BV, Leiden, Netherlands, 11Seattle Rheumatology Associates, P.L.L.C., Seattle, WA

    Background/Purpose: EQUATOR (NCT03101670) was a randomized, 16-week, Phase 2, multicenter, double-blind, placebo (PBO)‑controlled trial of filgotinib (FIL) in patients with active PsA ( Mease P,…
  • Abstract Number: 1331 • ACR Convergence 2020

    Carotid Ultrasound Findings in Psoriatic Arthritis: A Case-control Study

    Dionicio Ángel Galarza-Delgado1, José Ramón Azpiri López2, Iris Jazmín Colunga Pedraza3, Diana Elsa Flores Alvarado4, Octavio Ilizaliturri Guerra4, Paola Fernanda Frausto Lerma3, Itzel Corina Zárate Salinas2, Alejandra Pérez Villar3, Mayra Alejandra Reyes Soto3, Salvador Lugo Pérez2 and Andrea Cecilia Garza Acosta5, 1Rheumatology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Nuevo Leon, Mexico, 2Cardiology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Mexico, 3Rheumatology service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Mexico, 4Rheumatology Service, Hospital Universitario “Dr. José Eleuterio González, Universidad Autónoma Nuevo León, Monterrey, Nuevo Leon, Mexico, 5Radiology Service, Hospital Universitario “Dr. José Eleuterio González, Universidad Autónoma Nuevo León, Monterrey, Nuevo Leon, Mexico

    Background/Purpose: Patients with psoriatic arthritis (PsA) have an increased risk of cardiovascular disease (CVD). The carotid ultrasound, which measures both carotid intima-media thickness (cIMT) and…
  • Abstract Number: 1361 • ACR Convergence 2020

    Secukinumab Significantly Decreased Joint Synovitis Measured by Power Doppler Ultrasonography in Biologic-naïve Patients with Active Psoriatic Arthritis: Primary (12-Week) Results from a Randomized, Placebo-Controlled Phase III Study

    Maria D’Agostino1, Georg Schett2, Alejandra López-Rdz3, Ladislav Šenolt4, Jose Maldonado-Cocco5, Ruben Burgos-Vargas6, Esperanza Naredo7, Philippe Carron8, Maarten Boers9, Anne-Marie Duggan10, Punit Goyanka11 and Corine Gaillez12, 1Université Versailles Saint Quentin, Ambroise Paré Hospital, Paris, France, 2Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, 3Dermatológico Country, Jalisco, Mexico, 4Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 5University of Buenos Aires School of Medicine, Buenos Aires, Argentina, 6Department of Rheumatology, General Hospital of Mexico, Ciudad de Mexico, Mexico, 7Department of Rheumatology, Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz, IIS Fundación Jiménez Díaz and Universidad Autónoma de Madrid, Madrid, Spain, 8Department of Rheumatology, University Hospital Ghent, Ghent, Belgium, 9Department of Epidemiology & Biostatistics, Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 10Novartis Ireland Limited, Dublin, Ireland, 11Novartis Healthcare Pvt. Ltd., Hyderabad, India, 12Novartis Pharma AG, Basel, Switzerland

    Background/Purpose: Power Doppler (PD) ultrasonography (PDUS) is a sensitive non-invasive imaging technology used to assess joint synovitis and enthesitis of psoriatic arthritis (PsA) in clinical…
  • Abstract Number: 1562 • ACR Convergence 2020

    Subclinical Joint Inflammation of Hands by Magnetic Resonance Imaging in Patients with Psoriatic Arthritis in Clinical Remission Compared to Active Disease

    Victoria Furer1, Ari Polachek2, David Levartovsky1, Jonathan Wollman3, Mirna Zureik3, Daphna Paran1, Hagit Sarbagil-Maman4, Sara Borok Lev-Ran1, Mark Berman1, Ilana Kaufman5, Adi Broide3, Valerie Aloush1, Yael Lahat goldstein1, Sharon Nevo3, Iris Eshed6 and Ori Elkayam3, 1Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 2Tel Aviv Sourasky Medical Center, Petah-Tikva, Israel, 3Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel, 4Tel-Aviv Sourasky Medical Center, Kiryat Ono, Israel, 5Tel Aviv Sourasky Medical Center, Petah-Tiqwa, Israel, 6Sheba Medical Center, Tel-Aviv, Israel

    Background/Purpose: Assessment of disease activity in psoriatic arthritis (PsA) is based on tender and swollen joint counts (TJC and SJC, respectively). Yet, the prevalence of…
  • Abstract Number: 2026 • ACR Convergence 2020

    Efficacy and Safety of Upadacitinib versus Placebo and Adalimumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial

    Iain McInnes1, Jaclyn K Anderson2, Marina Magrey3, Joseph Merola4, Yi Liu5, Mitsumasa Kishimoto6, Slawomir Jeka7, Cesar Pacheco Tena8, Xin Wang2, Liang Chen2, Patrick Zueger2, Aileen Pangan9 and Frank Behrens10, 1Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2AbbVie Inc., North Chicago, IL, 3Case Western Reserve University School of Medicine, Cleveland, OH, 4Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 5West China Hospital of Sichuan University, Sichuan, China (People's Republic), 6Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, 72nd Univ Hospital, CM UMK, Bydgoszcz, Poland, 8Universidad Autonoma de Chihuahua, Chihuahua, Chihuahua, Mexico, 9Abbvie Inc., La Grange, IL, 10CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany

    Background/Purpose: Upadacitinib (UPA), an oral, reversible, JAK inhibitor approved to treat rheumatoid arthritis (RA), is under evaluation for psoriatic arthritis (PsA). We assess efficacy and…
  • Abstract Number: 0170 • ACR Convergence 2020

    Utilizing Design Thinking to Develop a Decision Aid for Patients with Psoriasis and Psoriatic Arthritis

    Marilyn Wan1, Michele Almonte2, Joel Gelfand1 and Alexis Ogdie2, 1University of Pennsylvania, Philadelphia, 2University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Given the complexity of available treatment recommendations, patients with psoriatic disease would benefit from a process fostering shared decision-making using a patient-centered approach. True…
  • Abstract Number: 0319 • ACR Convergence 2020

    Target Outcomes in Psoriatic Arthritis: Simultaneous Achievement of ACR50-Psoriasis Area and Severity Index 100 and Beyond: Insights from Open-Label, Assessor-Blinded Study at Week 24

    Josef Smolen1, Frank Behrens2, Soyi Liu-Leage3, Christophe Sapin3, Inmaculada de la Torre3, Gabriella Meszaros3, Georg Schett4, Laure Gossec5, Andrew Östör6, Bernard Combe7 and Filip Van den Bosch8, 1Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, 2CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, 3Eli Lilly and Company, Indianapolis, IN, 4Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, 5Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, 6Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, 7University of Montpellier, Montpellier, France, 8Ghent University Hospital, Ghent, Belgium

    Background/Purpose: Psoriatic Arthritis (PsA) treatment should aim to achieve robust improvement of arthritis as well as control of extra-articular manifestations like the skin. SPIRIT-H2H evaluated…
  • Abstract Number: 0335 • ACR Convergence 2020

    Interleukin-17 Blockade Leads to Shifts from Stage-based Towards Response-based Disease Clusters- Comparative Data from Very Early and Established Psoriatic Arthritis

    Eleni Kampylafka1, Koray Tascilar2, Veronika Lerchen3, Chistina Linz3, Maria Sokolova3, Ana Zekovic3, Arnd Kleyer2, David Simon2, Juergen Rech2, Michael Sticherling1, Georg Schett4 and Axel Hueber3, 1Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 2Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 3Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander- University Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, 4Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany

    Background/Purpose: Limited information exists about the very early forms of psoriatic arthritis (PsA). In particular, differences and responsiveness of patient-reported outcomes (PROs) in very early…
  • 1
  • 2
  • 3
  • …
  • 37
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.